Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer DOI Creative Commons

Shouhua Li,

Hengtong Han,

Kaili Yang

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 144, С. 113702 - 113702

Опубликована: Ноя. 26, 2024

Язык: Английский

Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development DOI Open Access

Yiyuan Feng,

Caiying He,

Chang Liu

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(12), С. 6444 - 6444

Опубликована: Июнь 11, 2024

Cancer represents a significant threat to human health, and traditional chemotherapy or cytotoxic therapy is no longer the sole preferred approach for managing malignant tumors. With advanced research into immunogenicity of tumor cells growing elderly population, immunotherapy has emerged as prominent therapeutic option. Its significance in treating cancer patients increasingly recognized. In this study, we review conceptual classifications benefits immunotherapy, discuss recent developments new drugs clinical progress treatment through various immunotherapeutic modalities with different mechanisms. Additionally, explore impact immunosenescence on effectiveness propose innovative effective strategies rejuvenate senescent T cells.

Язык: Английский

Процитировано

1

Capturing Hydrophilic Chemotherapeutics Agents Into siRNA‐Encapsulated Vesicle‐Like Nanoparticles for Convenient ICB‐Chemo Combination Therapy DOI Open Access
Yan Li, Bingqin Li, Chaoran Chen

и другие.

Small, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 5, 2024

Abstract Clinical evidence has demonstrated that combining immune checkpoint blockade (ICB) therapy with chemotherapy significantly improves response rates to ICB and therapeutic efficacy in various tumor types. However, a convenient method for achieving synergistic precise co‐delivery of both agents is still highly desirable. In this study, strategy co‐delivering small interfering RNA (siRNA) encapsulated vesicle‐like nanoparticles (VNP siRNA ) chemotherapeutic drugs aimed develop. It discovered the hydrophilic drug mitoxantrone hydrochloride (MTO·2HCl) can be captured into VNP . The resulting Cp MTO simultaneously block checkpoints via silencing induce effects on cells. mechanism MTO·2HCl elucidates, captures, demonstrates superior effect through chemo‐immunotherapy. This also extended deliver other anticancer drugs, such as doxorubicin (DOX·HCl), combination therapy. study provides facile enhancing combined offering promising approach cancer treatment.

Язык: Английский

Процитировано

0

Emerging role of metabolic reprogramming in the immune microenvironment and immunotherapy of thyroid cancer DOI Creative Commons

Shouhua Li,

Hengtong Han,

Kaili Yang

и другие.

International Immunopharmacology, Год журнала: 2024, Номер 144, С. 113702 - 113702

Опубликована: Ноя. 26, 2024

Язык: Английский

Процитировано

0